EscitalopramSerotonin reuptake inhibitor CAS# 128196-01-0 |
- Fulvestrant
Catalog No.:BCC1081
CAS No.:129453-61-8
- Bazedoxifene HCl
Catalog No.:BCC4492
CAS No.:198480-56-7
- XCT790
Catalog No.:BCC5121
CAS No.:725247-18-7
- Toremifene Citrate
Catalog No.:BCC4487
CAS No.:89778-27-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 128196-01-0 | SDF | Download SDF |
PubChem ID | 146570 | Appearance | Powder |
Formula | C20H21FN2O | M.Wt | 324.39 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile | ||
SMILES | CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F | ||
Standard InChIKey | WSEQXVZVJXJVFP-FQEVSTJZSA-N | ||
Standard InChI | InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Escitalopram Dilution Calculator
Escitalopram Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0827 mL | 15.4135 mL | 30.8271 mL | 61.6542 mL | 77.0677 mL |
5 mM | 0.6165 mL | 3.0827 mL | 6.1654 mL | 12.3308 mL | 15.4135 mL |
10 mM | 0.3083 mL | 1.5414 mL | 3.0827 mL | 6.1654 mL | 7.7068 mL |
50 mM | 0.0617 mL | 0.3083 mL | 0.6165 mL | 1.2331 mL | 1.5414 mL |
100 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.6165 mL | 0.7707 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Escitalopram (Lexapro,Cipralex)is a selective inihibitor of serotonin(5-HT) reuptake (SSRI) with a Ki value of 6.6nM for [3H]-5-HT uptake [1].
Escitalopram is the S-(+)-enantiomer of citalopram and has the inhibition of [3H]-5-HT uptake and [125I]-RTI-55 binding in COS-1 cells expressing the human serotonin transporter (5-HTT) with Ki values of 6.6±1.4nM and 3.9±2.2nM, respectively. In addition, Escitalopram has been reported to inhibit the accumulation of 3H-labelled monoamines into rat brain synaptosomes in vitro with IC50 values of 2.1±0.75nM, 2500±202nM and 40000±15500nM for [3H]-5-HT, [3H]-I-NA and [3H]-DA, respectively. Apart from these, Escitalopram has shown the in vitro affinity for rat histamine H1 receptors and the rat sigma σ1 site with Ki values of 1500±780nM and 100±71nM, respectively [1].
References:
[1] Sánchez C1, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. Epub 2003 Apr 26.
- Fmoc-D-Ser(tBu)-OH
Catalog No.:BCC3548
CAS No.:128107-47-1
- erythro-1-(4-Hydroxy-3-methoxyphenyl)propane-1,2-diol
Catalog No.:BCN1588
CAS No.:1280602-81-4
- Arvanil
Catalog No.:BCC7026
CAS No.:128007-31-8
- Sennoside B
Catalog No.:BCN1003
CAS No.:128-57-4
- Pregnanolone
Catalog No.:BCC7736
CAS No.:128-20-1
- Ursodiol
Catalog No.:BCC4945
CAS No.:128-13-2
- Teucrin A
Catalog No.:BCC8259
CAS No.:12798-51-5
- CU CPT 4a
Catalog No.:BCC6319
CAS No.:1279713-77-7
- 24(31)-Dehydrocarboxyacetylquercinic acid
Catalog No.:BCN1589
CAS No.:127970-62-1
- CGP 39551
Catalog No.:BCC7053
CAS No.:127910-32-1
- CGP 37849
Catalog No.:BCC7078
CAS No.:127910-31-0
- C-type natriuretic peptide (1-22) (human, rat, swine)
Catalog No.:BCC6033
CAS No.:127869-51-6
- N-ArachidonylGABA
Catalog No.:BCC7186
CAS No.:128201-89-8
- (R,R)-2,6-Bis(4-phenyl-2-oxazolin-2-yl)pyridine
Catalog No.:BCC8397
CAS No.:128249-70-7
- GDC-0032
Catalog No.:BCC4066
CAS No.:1282512-48-4
- BAY-X 1005
Catalog No.:BCC6038
CAS No.:128253-31-6
- Pachyaximine A
Catalog No.:BCN6152
CAS No.:128255-08-3
- Axillaridine A
Catalog No.:BCN6153
CAS No.:128255-16-3
- 1-(3,4-Dimethoxycinnamoyl)piperidine
Catalog No.:BCN4036
CAS No.:128261-84-7
- Bivalirudin Trifluoroacetate
Catalog No.:BCC1421
CAS No.:128270-60-0
- 2alpha-Hydroxy-8beta-(2-methylbutyryloxy)costunolide
Catalog No.:BCN7319
CAS No.:128286-87-3
- MK-8033 hydrochloride
Catalog No.:BCC4040
CAS No.:1283000-43-0
- Cinalukast
Catalog No.:BCC7244
CAS No.:128312-51-6
- MCH (human, mouse, rat)
Catalog No.:BCC6068
CAS No.:128315-56-0
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.[Pubmed:28255239]
Neuropsychiatr Dis Treat. 2017 Feb 17;13:515-526.
BACKGROUND: Significant anxiety symptoms are associated with poor clinical course and outcome in major depressive disorder (MDD). This single-arm, open-label study aimed to evaluate the efficacy and tolerability of Escitalopram treatment in patients with MDD and anxiety symptoms. METHODS: Adult patients with MDD and anxiety symptoms (Montgomery-Asberg Depression Rating Scale [MADRS] >/=22 and Hamilton Anxiety Rating Scale [HAM-A] >/=14) were enrolled and received Escitalopram (10-20 mg/day) treatment for 24 weeks. Symptom status was assessed by MADRS, 17-item-Hamilton Depression Rating Scale, HAM-A, and Clinical Global Impression Scale at baseline and the following visits. Quality of life was assessed by Short Form-12, and safety was evaluated by adverse events, laboratory investigations, vital signs, and physical findings. RESULTS: Overall, 200 of 318 (66.2%) enrolled patients completed the 24-week treatment. The remission (MADRS =10 and HAM-A =7) rate in the full analysis set (N=285) was 73.3% (95% confidence interval: 67.80, 78.38) at week 24. Mean (+/- standard deviation) MADRS total score was 33.4 (+/-7.13) and HAM-A score was 27.6 (+/-7.26) at baseline, which reduced to 6.6 (+/-10.18) and 6.0 (+/-8.39), respectively, at week 24. Patients with higher baseline depression and anxiety level took longer to achieve similar remission rates. Overall, 80 of the 302 (26.5%) patients included in the safety set reported at least 1 treatment-emergent adverse event (TEAE). Most frequently reported TEAEs (>2%) were headache (4.0%), nasopharyngitis (3.6%), nausea (3.0%), and dizziness (2.6%). Serious TEAEs were reported by 1.3% patients; no deaths were reported. CONCLUSION: Escitalopram 10-20 mg/day was effective and well-tolerated in the long-term treatment of MDD with anxiety symptoms in adult Chinese population.
The impact of childhood maltreatment on the differential efficacy of CBASP versus escitalopram in patients with chronic depression: A secondary analysis.[Pubmed:28326653]
Clin Psychol Psychother. 2017 Sep;24(5):1155-1162.
Childhood maltreatment (CM) has been indicated as a predictor of a differential response to antidepressant treatment with psychotherapy compared to medication. In this secondary analysis, we investigated whether the presence of CM results in a differential indication for the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) or Escitalopram plus clinical management (ESC). Sixty patients with chronic depression were randomized to either 22 sessions of CBASP or ESC over the course of 8 weeks of acute and 20 weeks of extended treatment at 2 German treatment sites. CM was assessed using the Childhood Trauma Questionnaire and the clinician rated Early Trauma Inventory. Intention-to-treat analyses were used to examine the impact of CM on depression, global functioning, and quality of life. The presence of CM did not result in significant differences in treatment response to CBASP or ESC on any outcome measure after 28 weeks of treatment independent of the type of CM assessment. After 8 weeks, a significant CM x treatment interaction was found for scores on the Montgomery-Asberg Depression Rating Scale. Patients with a history of CM receiving CBASP had a significantly lower response rate compared to patients without CM and to those receiving ESC after 8 weeks. Conclusively, CBASP and ESC are equally effective treatment options for the difficult to treat subgroup of patients with chronic depression and a history of CM. CM may be a predictor of a longer latency of treatment response in the case of psychotherapy. KEY PRACTITIONER MESSAGE: CBASP and Escitalopram are equally effective treatment options for chronic depression. Both treatments are also equally effective for the difficult to treat subgroup of patients with chronic depression and a history of childhood maltreatment. Childhood maltreatment may result in a longer latency of treatment response in the case of psychotherapy.
Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.[Pubmed:28299626]
Metab Brain Dis. 2017 Jun;32(3):891-901.
Severe depression accounts for one-third of depressed patients. Increasing severity of depression usually hinders patients from achieving remission. This study evaluated the efficacy and safety of Escitalopram in acute-phase treatment of severe major depressive disorder (MDD). A total of 225 participants with severe MDD (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria), with a current depressive episode and Montgomery-Asberg Depression Rating Scale (MADRS) score of >/=30 were enrolled. Participants received flexible dose Escitalopram (10-20 mg/d) treatment for 8 weeks. Symptoms status was assessed by MADRS, Hamilton Depression Rating Scale (HAM-D-17), and Hamilton Anxiety Rating Scale (HAM-A). Quality of life was assessed by Short Form-12 (SF-12) and safety by adverse events, laboratory investigations, vital signs and physical findings. The remission (MADRS total score = 10) rate in the intent-to-treat set (n = 207) was 72.9% at week 8. Significant improvement in symptoms compared to baseline, as evaluated by MADRS, HAMD-17 and HAMA scores at baseline, week 1, week 2, week 4, and week 8 (p < 0.0001 for all), was noted. Mean (SD) reduction from baseline in MADRS total score was 26.6 (11.38). Improvements in SF-12 score were significant (p = 0.000) and positively related to symptom improvement and negatively related to treatment-emergent adverse events (TEAEs). TEAEs were reported in 28.38% of participants. Most common TEAEs (>4%) were somnolence (9.0%), nausea (7.7%), hyperhidrosis (4.5%), dry mouth and dizziness (4.1% each). No serious TEAEs were reported. Escitalopram was effective and well-tolerated for acute-phase treatment of severe depression in Chinese population.